INO
Inovio Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Inovio Pharmaceuticals, Inc. (INO) closed at $1.58 as of 2026-03-20, trading 81.9% below its 200-week moving average of $8.74. This places INO in the extreme value zone. The stock is currently moving closer to the line, down from -81.2% last week. The 14-week RSI sits at 35, indicating neutral momentum.
Trading volume is running at 0.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.98 ratio) is neutral — neither side is clearly dominating.
Over the past 1375 weeks of data, INO has crossed below its 200-week moving average 20 times. On average, these episodes lasted 51 weeks. The average one-year return after crossing below was -29.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $109 million, INO is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -183.5%. The stock trades at 4.5x book value.
Share count has increased 227.1% over three years, indicating dilution.
Over the past 26.4 years, a hypothetical investment of $100 in INO would have grown to $0, compared to $743 for the S&P 500. INO has returned -19.8% annualized vs 7.9% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: INO vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After INO Crosses Below the Line?
Across 20 historical episodes, buying INO when it crossed below its 200-week moving average produced an average return of -35.5% after 12 months (median -28.0%), compared to +6.3% for the S&P 500 over the same periods. 10% of those episodes were profitable after one year. After 24 months, the average return was -46.9% vs +11.1% for the index.
Each line shows $100 invested at the moment INO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
INO has crossed below its 200-week MA 20 times with an average 1-year return of +-29.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 1999 | Jan 2000 | 8 | 13.1% | -59.2% | -99.7% |
| May 2000 | Dec 2003 | 187 | 92.9% | -62.8% | -99.8% |
| Aug 2004 | Aug 2004 | 1 | 6.8% | -14.0% | -98.9% |
| Sep 2004 | Nov 2004 | 8 | 19.8% | -4.2% | -98.9% |
| Nov 2004 | Dec 2004 | 3 | 7.1% | -28.4% | -99.0% |
| Apr 2005 | May 2005 | 2 | 3.0% | -22.0% | -98.9% |
| May 2005 | Jun 2005 | 3 | 17.4% | -21.7% | -98.9% |
| Jul 2005 | Oct 2006 | 66 | 35.9% | -29.0% | -98.9% |
| Oct 2006 | Oct 2006 | 1 | 4.4% | -63.3% | -99.0% |
| Nov 2006 | Apr 2007 | 22 | 13.6% | -65.1% | -99.0% |
| May 2007 | Jul 2009 | 113 | 92.1% | -78.0% | -99.1% |
| Sep 2009 | Jan 2011 | 67 | 41.5% | -20.5% | -97.7% |
| Mar 2011 | Jul 2013 | 122 | 61.2% | -44.7% | -97.1% |
| Sep 2015 | Nov 2015 | 5 | 6.1% | +57.7% | -97.8% |
| Dec 2015 | Dec 2015 | 1 | 4.7% | +14.8% | -97.9% |
| Jan 2016 | Feb 2016 | 8 | 23.6% | +26.4% | -97.7% |
| Oct 2016 | Mar 2020 | 175 | 63.9% | -9.3% | -98.0% |
| May 2021 | May 2021 | 1 | 2.8% | -69.6% | -98.0% |
| Sep 2021 | Nov 2021 | 6 | 6.5% | -74.2% | -98.0% |
| Nov 2021 | Ongoing | 225+ | 94.5% | Ongoing | -97.9% |
| Average | 51 | — | +-29.8% | — |
Frequently Asked Questions
Is INO below its 200-week moving average?
Yes. As of 2026-03-20, Inovio Pharmaceuticals, Inc. (INO) is trading 81.9% below its 200-week moving average of $8.74. The current price is $1.58.
What is INO's 200-week moving average price?
Inovio Pharmaceuticals, Inc.'s 200-week moving average is $8.74 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when INO drops below its 200-week moving average?
INO has crossed below its 200-week moving average 20 times in our data. The average one-year return after these crossings was -29.8%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 51 weeks on average.
Is INO a good value right now?
Here's what our data says about INO as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 35. Free cash flow is currently negative. Return on equity is -183.5%. Price-to-book is 4.5x. This is not a buy or sell recommendation — always do your own research.
How does INO compare to the S&P 500?
Over the past 26.4 years, $100 invested in INO would have grown to $0, compared to $743 for the S&P 500. That's -19.8% annualized vs 7.9% for the index. INO has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20